Post-earnings recap
Reported
Thu, Jul 30, 2026
EPS actual
$14.29
EPS est.
$8.00
EPS surprise
+78.63%
1-day move
+6.17%
Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company focused on developing and commercializing innovative medicines for serious diseases. With a market cap of $83 billion, it plays a significant role in the health care sector, particularly in the development of treatments for conditions like cancer and eye diseases.
Last quarter
In Q1 2026, Regeneron reported an EPS of $9.47, significantly beating expectations of $6.28, leading to a stock decline of 6.21% the following day. The strong earnings surprise reflects the company's ability to outperform analyst predictions.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+49.12%
Avg 1-day reaction
+0.21%
Analysts are optimistic about Regeneron's upcoming earnings, expecting strong EPS and revenue figures. The company's recent performance suggests it has the potential to continue exceeding expectations.
Bull case
If Regeneron delivers an EPS above $15.36 and revenue near or above $4.5 billion, it could signal robust demand for its products and further growth potential.
Bear case
Conversely, if the company fails to meet these expectations, it could raise concerns about its growth trajectory and lead to a negative market reaction.
Key metrics to watch
EPS
$15.36Earnings per share is a key indicator of profitability, and analysts expect a strong performance this quarter.
Revenue
$4.5BRevenue figures will provide insight into the company's sales performance and overall growth.
The print will turn on these.
Q1
Will Regeneron achieve an EPS of $15.36 or higher?
This specific EPS target is crucial for assessing the company's profitability and growth potential.
Q2
What will be the revenue figure relative to the $4.5 billion consensus?
Revenue performance will indicate the company's sales strength and market demand for its products.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±13.6%
Why consensus could be wrong
The Street may be underestimating Regeneron's ability to sustain high growth rates, given its recent performance and product pipeline.
Supporting evidence
Regeneron has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.
The options market is pricing in a larger move than historical averages, suggesting that traders expect significant volatility.
The company's recent product launches may not be fully reflected in analyst revenue estimates.
Key risk
If the company reports revenue significantly below $4.5 billion, it could challenge the current bullish sentiment.
Pre-commit to what would confirm each case.
The market is debating the sustainability of Regeneron's growth, with strong historical performance suggesting potential upside.
Bull confirmed if
An EPS of $15.36 or higher with revenue exceeding $4.5 billion would confirm the bull case.
Bear confirmed if
An EPS below $13.87 or revenue below $4.2 billion would confirm the bear case.
What the market is pricing for the move.
Implied Move
±13.18%
Historical Avg
±5.43%
The options market is pricing in a significant move around the earnings report, indicating that investors expect volatility.
Options price a 13.18% move, while the stock has averaged only 5.43% over the last 8 quarters — setup is rich.
ATM IV
0.3%
30d HV
41.1%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
93.56%
of float
Insider
2.08%
of float
Holders
1,912
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
9,113,506 sh · $6.8B
9.01%
1.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Regeneron beats expectations, history suggests the stock could see an average one-day move of +2.89%, confirming strong demand.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.
Miss
A miss could lead to a decline, with history suggesting an average one-day move of -0.40% when expectations are not met.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
6,629,759 sh · $4.9B
6.56%
-0.4%
Dodge & Cox Inc.
4,871,137 sh · $3.6B
4.82%
9.3%
State Street Corporation
4,834,688 sh · $3.6B
4.78%
3.6%
Invesco Ltd.
3,940,665 sh · $2.9B
3.90%
0.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded May 15, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.